ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 37 of 200 for:    Oral Cancer | Recruiting Studies | NIH

The Pittsburgh Vitamin D Study: Vitamin D Supplementation in Vitamin D-deficient Subjects at Risk of Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02532062
Recruitment Status : Recruiting
First Posted : August 25, 2015
Last Update Posted : June 23, 2017
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
David O. Wilson, University of Pittsburgh

Brief Summary:
This study aims to establish the ability of 4,000 IU oral vitamin D3 per day (in combination with a daily multivitamin) to safely convert vitamin D3-deficient subjects at increased risk of lung cancer to a vitamin D3-sufficient state, and to explore effects of vitamin D3 supplementation in this population on markers of inflammation and lung cancer risk. Current and former smokers with chronic obstructive pulmonary disease (COPD) are at increased risk of developing lung cancer and represent the clinical population of interest for this study.

Condition or disease Intervention/treatment Phase
Deficiency of Vitamin D3 COPD Dietary Supplement: Cholecalciferol Dietary Supplement: multivitamin Dietary Supplement: Placebo Phase 2

Detailed Description:

Smoking avoidance or cessation are essential to the prevention of lung cancer. However, not all smokers are able to quit smoking and, importantly, former smokers remain at increased risk of lung cancer compared to never smokers. Despite smoking prevention/cessation programs and treatment advances, lung cancer is still the leading cause of cancer-related mortality in the United States with more than 158,000 individuals expected to die from this disease in 2015. Effective and safe prevention strategies are expected to be more successful in reducing lung cancer deaths than treatment of established disease.

NF-kappaB (NF-kB) pathway activation underlies smoking-related inflammation and lung carcinogenesis, and those agents which suppress NF-κB signaling may have the potential to prevent lung cancer. Recent preclinical data from our group and others indicate that the active metabolite of vitamin D3, 1,25-dihydroxyvitamin D3 [1,25(OH)2D3], has lung cancer chemopreventive activity. Because systemic 1,25(OH)2D3 administration is complicated by its hypercalcemia-inducing properties, the investigators propose to use oral supplementation with vitamin D3 (cholecalciferol) to safely achieve chemopreventive 1,25(OH)2D3 levels within the lung.

This randomized, placebo-controlled Phase IIb study aims to evaluate the ability of 4,000 IU oral vitamin D3/day (in combination with a daily multivitamin) to safely convert vitamin D3-deficient subjects at risk of lung cancer to a vitamin D3-sufficient state.

Study participants will be recruited from among Pittsburgh Lung Screening Study Extension (PLuSS-X) and PLuSS-XX participants not diagnosed with lung cancer, and from among the patient population seen by the PI of this protocol. The study consists of two stages, a screening and an intervention stage, with their own consent forms. In Stage 1 (the screening stage), the vitamin D3 status of subjects potentially eligible for participation in the intervention will be determined; in Stage 2 (the intervention stage), supplementation with oral vitamin D3 will be evaluated.

Participants who fulfill the eligibility criteria and provided signed consent for Stage 2 will be randomized in a 2:1 ratio to receive: (A) 4,000 IU vitamin D3 plus a multivitamin (containing 400 IU vitamin D3) daily for one year, or (B) a placebo vitamin D3 pill plus a multivitamin daily for one year. Both groups will contain equal numbers of current and ex-smokers; in total 120 subjects will be randomized. To evaluate whether supplementation safely corrects vitamin D3 deficiency in this population, blood samples will be obtained at baseline, 3, 6, and 12 months of intervention for evaluation of 25(OH)D3 and serum calcium. The collected blood will also be used to facilitate biomarker assessment. Pulmonary function tests (PFTs) will be obtained at baseline and repeated after 12 months to determine whether supplementation has an effect on lung function. Sputum and nasal epithelium will be collected at baseline, 6 months and 12 months to facilitate biomarker assessment.

- Study Objectives Primary Objective: To establish the 12-month conversion rate (i.e., proportion of subjects whose baseline vitamin D3 deficiency is corrected after 12 months of supplementation).

Secondary Objectives: To determine the 3-month and 6-month conversion rates and examine the effect of vitamin D3 supplementation in current and former smokers. Additionally, to examine the effects of vitamin D3 supplementation on biomarkers of lung cancer risk, inflammation, and pulmonary function.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 120 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Efficacy of Vitamin D Supplementation in Vitamin D-deficient Subjects at Risk of Lung Cancer (The Pittsburgh Vitamin D Study)
Study Start Date : January 2016
Estimated Primary Completion Date : January 2019
Estimated Study Completion Date : September 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Supplementation
Participants who are assigned to the Supplementation arm will receive a vitamin D supplement containing 4,000 units of vitamin D3 (cholecalciferol; capsule form) plus an oral multivitamin containing 400 units of vitamin D3 daily for a period of one year.
Dietary Supplement: Cholecalciferol
4,000 IU, oral, once a day for one year
Other Name: Vitamin D3

Dietary Supplement: multivitamin
oral, once a day for one year

Active Comparator: Placebo
Participants who are assigned to the Placebo arm will receive a placebo supplement plus an oral multivitamin containing 400 units of vitamin D3 daily for a period of one year.
Dietary Supplement: multivitamin
oral, once a day for one year

Dietary Supplement: Placebo
oral, once a day for one year




Primary Outcome Measures :
  1. The 12-month conversion rate [ Time Frame: 12 months ]
    The proportion of subjects whose baseline vitamin D3 deficiency is corrected after 12 months of supplementation (i.e., the 12-month conversion rate).


Secondary Outcome Measures :
  1. The 3-month conversion rate [ Time Frame: 3 months ]
  2. The 6-month conversion rate [ Time Frame: 6 months ]
  3. Pulmonary function as measured by spirometry [ Time Frame: 12 months ]
    Effect of vitamin D supplementation on lung function as measured by spirometry will be evaluated.

  4. Promoter methylation status in sputum and nasal swab samples [ Time Frame: 12 months ]
    Effect of supplementation on promoter methylation status of genes previously reported associated with lung cancer risk (e.g., RAMP2, p16, MGMT) in sputum and nasal swab samples will be explored.

  5. Protein expression in sputum and nasal swab samples [ Time Frame: 12 months ]
    Effect of supplementation on the expression of proteins, including inflammation and vitamin D metabolism-related proteins, in sputum and nasal swab samples will be explored.

  6. Concentration of inflammatory markers in blood [ Time Frame: 12 months ]
    Blood samples will be analyzed for inflammatory markers such as IL6 and CRP and the effect of supplementation on the examined cytokines will be explored.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   50 Years to 85 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age ≥ 50 years old.
  2. Current or ex-smoker with at least 10 pack-year history
  3. COPD, GOLD II or greater (defined as FEV1/FVC <70% and FEV1 % predicted <80%)
  4. 25(OH)D3 level ≤25 ng/mL
  5. Willingness to comply with study guidelines.
  6. Willingness to avoid alternative/additional vitamin D3 supplementation for the duration of the trial
  7. Participant must understand the investigational nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written informed consent form prior to receiving any study related procedure.

Exclusion Criteria:

  1. Personal history of lung cancer or head and neck cancer
  2. History of malabsorption syndrome (e.g., pancreatic insufficiency, celiac disease, or tropical sprue).
  3. History of known thyroid disease
  4. History of known sarcoid disease
  5. History of known abnormalities in calcium metabolism
  6. Hypercalcemia (serum calcium in excess of laboratory ULN)
  7. Self-reported consumption of more than 4 alcoholic drinks per day
  8. Use of anti-seizure medications phenobarbital or phenytoin, which can disrupt vitamin D metabolism
  9. History of known renal dysfunction
  10. History of known nephrolithiasis (kidney stones)
  11. Current participation in another cancer chemoprevention study
  12. Any condition which in the Investigator's opinion deems the subject an unsuitable candidate to receive study drug.
  13. Inability to swallow pills.
  14. Vitamin D supplementation > 2,000 IU/day of vitamin D within 30 days prior to enrollment.
  15. Being pregnant

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02532062


Contacts
Contact: David Wilson, MD 412-687-3355 wilsondo@upmc.edu
Contact: Brenda Diergaarde, PhD 412-623-5891 diergaardeb@upmc.edu

Locations
United States, Pennsylvania
University of Pittsburgh Cancer Institute Recruiting
Pittsburgh, Pennsylvania, United States, 15232
Contact: David Wilson, MD    412-687-3355    wilsondo@upmc.edu   
Contact: Brenda Diergaarde, PhD    412-623-5891    diergaardeb@upmc.edu   
Sponsors and Collaborators
University of Pittsburgh
National Cancer Institute (NCI)
Investigators
Principal Investigator: David Wilson, MD University of Pittsburgh

Responsible Party: David O. Wilson, MD, MPH, Associate Professor of Medicine, University of Pittsburgh
ClinicalTrials.gov Identifier: NCT02532062     History of Changes
Other Study ID Numbers: PRO15020031
P50CA090440 ( U.S. NIH Grant/Contract )
First Posted: August 25, 2015    Key Record Dates
Last Update Posted: June 23, 2017
Last Verified: June 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided

Keywords provided by David O. Wilson, University of Pittsburgh:
lung cancer risk
cigarette smokers

Additional relevant MeSH terms:
Lung Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Neoplasms
Lung Diseases
Respiratory Tract Diseases
Vitamins
Vitamin D
Ergocalciferols
Cholecalciferol
Micronutrients
Growth Substances
Physiological Effects of Drugs
Bone Density Conservation Agents